Summary

Real-world data and real-world evidence are used to monitor the post-market safety and adverse events of drugs. The monitoring of this data assists in making regulatory decisions. The healthcare community is using RWE and RWD to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice.
The global RWE solutions market is projected to reach USD 2.3 billion by 2026 from USD 1.2 billion in 2021, at a CAGR of 14.4% during the forecast period. The rising geriatric population (and the subsequent increase in the prevalence of chronic diseases) is a key factor driving the growth of this market. The shift from volume- to value-based care, delays in drug development (and the subsequent increase in development costs), growth in R&D spending, and support from regulatory bodies for the use of RWE solutions are some of the other major factors that are driving the growth of this market. However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection are restraining the growth of this market.
“The Services segment accounted for the largest market share in 2020.”
Based on component, the market is segmented into data sets and services. In 2020, the services segment accounted for a larger share of 58.8% of the global RWE solutions market. This segment is also estimated to grow at the highest CAGR of 16.0% during the forecast period. The rising need to convert data into actionable evidence, the growing need to reduce drug development delays, and the availability of a large volume of healthcare data are the major factors driving the growth of this market segment.
“The Oncology segment accounted for the largest market share in 2020.”

Based on the therapeutic area, the RWE solutions market is broadly categorized into oncology, neurology, immunology, cardiovascular disease, and other therapeutic areas. The oncology segment accounted for the largest share of 24.8% of the RWE solutions market in 2020. This segment is projected to reach USD 560.5 million by 2026 from USD 285.5 million in 2021, at a CAGR of 14.4% during the forecast period. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.
“The Pharmaceutical and Medical Device Companies segment accounted for the largest market share in 2020.”
Based on end user, the RWE solutions market is broadly segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users (CROs, academic institutions, patient advocacy groups, and health technology assessment agencies). The pharmaceutical & medical device companies segment accounted for the largest share of 46.3% of the RWE solutions market in 2020. This segment is also estimated to grow at the highest CAGR of 16.8% during the forecast period. The large share and high growth of this end-user segment can be attributed to the increasing importance of RWE studies in drug approvals, the need to prevent costly drug recalls, and the increasing need to assess drug performance in real-world settings.


“North America was the largest regional market for real world evidence solutions market in 2020“

The global RWE solutions market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 60.8% of the global market. Factors such as the favorable regulatory environment, the increasing number of payers using RWD, the growing number of RWE service providers, and the increasing number of pharmaceutical companies adopting RWE for drug approval processes are driving the growth of the RWE solutions market in North America. The Asia Pacific market, however, is estimated to grow at the highest CAGR during the forecast period. The increasing government initiatives for the adoption of RWE studies, the rising burden of chronic diseases, increasing demand for better healthcare services, and the increasing geriatric population are driving the growth of the RWE solutions market in the Asia Pacific.

The break-down of primary participants is as mentioned below:
• By Company Type - Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
• By Designation - C-level: 25%, Director-level: 55%, and Others: 20%
• By Region - North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 5%

Research Coverage:
The report analyzes the real world evidence solutions market and aims at estimating the market size and future growth potential of various market segments, based on by component, therapeutic area, end user and region.
The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
 Market Penetration: Comprehensive information on the product portfolios of the top players in the real world evidence solutions market. The report analyzes this market by type of component, therapeutic area, end user and region.
 Market Development: Comprehensive information on the lucrative emerging markets, by type of component, therapeutic area, end user and region.
 Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the real world evidence solutions market
 Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the real world evidence solutions market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS AND EXCLUSIONS 26
1.2.2 MARKETS COVERED 26
1.2.3 YEARS CONSIDERED FOR THE STUDY 27
1.3 CURRENCY 27
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 27
1.4 LIMITATIONS 27
1.5 STAKEHOLDERS 28
1.6 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
FIGURE 1 RESEARCH DESIGN 30
2.1.1 SECONDARY DATA 31
2.1.1.1 Key data from secondary sources 32
2.1.2 PRIMARY DATA 32
FIGURE 2 PRIMARY SOURCES 33
2.1.2.1 Key data from primary sources 34
2.1.2.2 Insights from primary experts 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 35
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 36
2.2 MARKET SIZE ESTIMATION: RWE SOLUTIONS MARKET 36
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 37
FIGURE 6 CAGR PROJECTIONS: OVERALL REAL-WORLD EVIDENCE SOLUTIONS MARKET 38
2.2.1 TOP-DOWN APPROACH 38
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 40
FIGURE 7 DATA TRIANGULATION METHODOLOGY 40
2.4 MARKET RANKING ANALYSIS 41
2.5 ASSUMPTIONS FOR THE STUDY 41
2.6 RISK ASSESSMENT 42
TABLE 2 RISK ASSESSMENT: REAL-WORLD EVIDENCE SOLUTIONS MARKET 42
2.7 LIMITATIONS 42
2.7.1 METHODOLOGY-RELATED LIMITATIONS 42
2.7.2 SCOPE-RELATED LIMITATIONS 42
3 EXECUTIVE SUMMARY 43
FIGURE 8 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2021 VS. 2026 (USD MILLION) 43
FIGURE 9 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2021 VS. 2026 (USD MILLION) 44
FIGURE 10 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 44
FIGURE 11 REAL-WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 45
4 PREMIUM INSIGHTS 46
4.1 REAL-WORLD EVIDENCE SOLUTIONS MARKET OVERVIEW 46
FIGURE 12 SUPPORT FROM REGULATORY BODIES FOR THE USE OF RWE SOLUTIONS IS A MAJOR FACTOR DRIVING THE MARKET GROWTH 46
4.2 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER AND COUNTRY (2020) 47
FIGURE 13 JAPAN ACCOUNTED FOR THE LARGEST SHARE OF THE
ASIA PACIFIC MARKET IN 2020 47
4.3 REAL-WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48
FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING
THE FORECAST PERIOD 48
4.4 REGIONAL MIX: REAL-WORLD EVIDENCE SOLUTIONS MARKET (2021−2026) 49
FIGURE 15 NORTH AMERICA WILL CONTINUE TO DOMINATE THE REAL-WORLD EVIDENCE SOLUTIONS MARKET DURING THE FORECAST PERIOD 49
4.5 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DEVELOPED VS. DEVELOPING MARKETS 49
FIGURE 16 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES
DURING THE FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
TABLE 3 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES:
IMPACT ANALYSIS 50
5.2.1 DRIVERS 51
5.2.1.1 Rising geriatric population and the subsequent increase in the prevalence of chronic diseases 51
FIGURE 17 GROWTH IN THE GERIATRIC POPULATION, BY REGION (2015–2050) 51
5.2.1.2 Shift from volume- to value-based care 52
5.2.1.3 Potential of RWE in reducing drug development costs and expediting the drug development process 52
5.2.1.4 Growth in R&D spending 53
FIGURE 18 INCREASING R&D SPENDING OF PHRMA MEMBER COMPANIES,
2010–2018 53
FIGURE 19 ACTIVE PHARMACEUTICAL PIPELINE, 2009–2019 54
5.2.1.5 Support from regulatory bodies for the use of RWE solutions 54
5.2.2 RESTRAINTS 55
5.2.2.1 Reluctance to rely on real-world studies 55
5.2.3 OPPORTUNITIES 55
5.2.3.1 Growth opportunities in emerging markets 55
5.2.3.2 Rising focus on end-to-end RWE services 57
5.2.4 CHALLENGES 57
5.2.4.1 Lack of universally accepted methodological standards and data processing infrastructure 57
5.2.4.2 Shortage of skilled professionals 57
6 INDUSTRY INSIGHTS 59
6.1 INDUSTRY TRENDS 59
6.1.1 EMERGING ROLE OF WEARABLE DEVICES 59
FIGURE 20 UTILIZATION OF WEARABLES IN CLINICAL TRIALS,
BY THERAPEUTIC AREA (2019) 59
6.1.2 SOCIAL MEDIA-SOURCED RWE 60
6.1.3 GROWING USE OF RWD AND RWE ACROSS THE PHARMACEUTICAL INDUSTRY 61
FIGURE 21 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE 61
6.1.4 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH 61
FIGURE 22 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH 62
6.1.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT 62
6.2 REAL-WORLD DATA SOURCES 63
TABLE 4 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES 63
6.3 ECOSYSTEM ANALYSIS 64
FIGURE 23 ECOSYSTEM COVERAGE: PARENT MARKET (HEALTHCARE IT SOLUTIONS) 65
FIGURE 24 ECOSYSTEM COVERAGE: REAL-WORLD EVIDENCE SOLUTIONS MARKET 65
6.4 COVID-19 IMPACT ON THE REAL-WORLD EVIDENCE SOLUTIONS MARKET 66
6.5 REGULATORY RECOMMENDATIONS FOR REAL-WORLD EVIDENCE SOLUTIONS 67
6.5.1 NORTH AMERICA 67
6.5.2 EUROPE 68
6.5.3 ASIA PACIFIC 69
6.5.3.1 China 69
6.6 HCIT EXPENDITURE/PRICING ANALYSIS 70
6.6.1 NORTH AMERICA 70
TABLE 5 NORTH AMERICA: HEALTHCARE EXPENDITURE, BY COUNTRY 70
6.6.2 EUROPE 70
6.6.3 ASIA PACIFIC 71
TABLE 6 JAPAN: HEALTHCARE IT INITIATIVES AND FUNDING 71
TABLE 7 CHINA: HEALTHCARE IT INITIATIVES AND FUNDING 72

7 RWE SOLUTIONS MARKET, BY COMPONENT 73
7.1 INTRODUCTION 74
TABLE 8 RWE SOLUTIONS MARKET, BY COMPONENT, 2019–2026 (USD MILLION) 74
7.2 SERVICES 74
7.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE THE DEMAND FOR RWE SERVICES 74
TABLE 9 RWE SERVICES OFFERED BY KEY MARKET PLAYERS 75
TABLE 10 RWE SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 75
7.3 DATA SETS 76
TABLE 11 RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 76
TABLE 12 RWE DATA SETS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 77
7.3.1 CLINICAL SETTINGS DATA 77
7.3.1.1 Increasing utilization of EHR data for trial recruitment to fuel the growth of this market segment 77
FIGURE 25 US: OFFICE-BASED PHYSICIAN EHR ADOPTION (2004–2017) 78
FIGURE 26 US: HOSPITAL EHR ADOPTION (2007–2018) 78
TABLE 13 CLINICAL SETTINGS DATA SET SOLUTIONS OFFERED
BY KEY MARKET PLAYERS 78
TABLE 14 RWE CLINICAL SETTINGS DATA MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 79
7.3.2 CLAIMS DATA 79
7.3.2.1 Growing need to understand the economic benefits of drug reimbursement by payers to drive growth in this market segment 79
TABLE 15 CLAIMS DATA SET SOLUTIONS OFFERED BY KEY MARKET PLAYERS 80
TABLE 16 RWE CLAIMS DATA MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 80
7.3.3 PHARMACY DATA 81
7.3.3.1 Increasing adoption of e-prescribing systems to drive the growth of this market segment 81
FIGURE 27 E-PRESCRIBING UTILIZATION AMONG PHARMACIES AND PRESCRIBERS IN THE US (2013–2017) 81
TABLE 17 PHARMACY DATA SET SOLUTIONS OFFERED BY KEY MARKET PLAYERS 82
TABLE 18 RWE PHARMACY DATA MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 82
7.3.4 PATIENT-POWERED DATA 83
7.3.4.1 Increasing need to access opinions on diseases and treatments across social media to drive the growth of this market segment 83
TABLE 19 PATIENT-POWERED DATA SET SOLUTIONS OFFERED BY KEY MARKET PLAYERS 83
TABLE 20 RWE PATIENT-POWERED DATA MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 83
8 RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA 84
8.1 INTRODUCTION 85
FIGURE 28 NUMBER OF CLINICAL TRIALS, BY THERAPEUTIC AREA, 2010–2017 85
TABLE 21 GLOBAL NUMBER OF CLINICAL TRIALS IN DIFFERENT
THERAPEUTIC AREAS, 2016–2020 85
TABLE 22 RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 86
8.2 ONCOLOGY 86
8.2.1 GROWING NUMBER OF CLINICAL TRIALS FOCUSED ON CANCER TREATMENT TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 86
FIGURE 29 INCIDENCE OF ALL TYPES OF CANCERS WORLDWIDE (2018) 86
TABLE 23 LIST OF PIPELINE DRUGS FOR ONCOLOGY (2018) 87
TABLE 24 RWE SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 88
8.3 CARDIOVASCULAR DISEASE 88
8.3.1 HIGH PREVALENCE OF CVD TO DRIVE THE GROWTH OF
THIS MARKET SEGMENT 88
TABLE 25 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASE (2018) 89
TABLE 26 RWE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2019–2026 (USD MILLION) 90
8.4 NEUROLOGY 90
8.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO
DRIVE THE GROWTH OF THIS MARKET SEGMENT 90
TABLE 27 RWE SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 91
8.5 IMMUNOLOGY 91
8.5.1 INCREASING FOCUS ON DEVELOPING INNOVATIVE PRODUCTS TO
DRIVE THE GROWTH OF THIS MARKET SEGMENT 91
TABLE 28 RWE SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 92
8.6 OTHER THERAPEUTIC AREAS 92
TABLE 29 RWE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 93
9 RWE SOLUTIONS MARKET, BY END USER 94
9.1 INTRODUCTION 95
TABLE 30 RWE SOLUTIONS MARKET, BY END USER, 2019–2026 (USD MILLION) 95
9.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES 95
9.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINE TO
DRIVE MARKET GROWTH 95
FIGURE 30 FDA PHASE TRANSITION SUCCESS RATES, 2006–2015 96
FIGURE 31 ANNUAL DRUG APPROVALS BY CDER (FDA), 2009–2018 97
FIGURE 32 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2011–2018 97
TABLE 31 RWE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 98
9.3 HEALTHCARE PAYERS 98
9.3.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO
DRIVE THE DEMAND FOR RWE SOLUTIONS 98
TABLE 32 RWE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY,
2019–2026 (USD MILLION) 99

9.4 HEALTHCARE PROVIDERS 99
9.4.1 RISING NEED TO IMPROVE THE PROFITABILITY OF HEALTHCARE OPERATIONS TO BOOST THE USE OF RWE SOLUTIONS 99
TABLE 33 RWE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2019–2026 (USD MILLION) 100
9.5 OTHER END USERS 100
TABLE 34 RWE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY,
2019–2026 (USD MILLION) 101
10 RWE SOLUTIONS MARKET, BY REGION 102
10.1 INTRODUCTION 103
TABLE 35 RWE SOLUTIONS MARKET, BY REGION, 2019–2026 (USD MILLION) 103
10.2 NORTH AMERICA 103
FIGURE 33 NORTH AMERICA: RWE SOLUTIONS MARKET SNAPSHOT 104
TABLE 36 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 104
TABLE 37 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 105
TABLE 38 NORTH AMERICA: RWE DATA SETS MARKET, BY TYPE,
2019–2026 (USD MILLION) 105
TABLE 39 NORTH AMERICA: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 105
TABLE 40 NORTH AMERICA: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 106
10.2.1 US 106
10.2.1.1 The US holds the largest share of the North American market 106
TABLE 41 US: NUMBER OF CLINICAL TRIALS STARTED, BY COMPANY, 2017 107
TABLE 42 US: MACROECONOMIC INDICATORS 107
TABLE 43 US: RWE SOLUTIONS MARKET, BY COMPONENT, 2019–2026 (USD MILLION) 107
TABLE 44 US: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 45 US: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 108
TABLE 46 US: RWE SOLUTIONS MARKET, BY END USER, 2019–2026 (USD MILLION) 108
10.2.2 CANADA 109
10.2.2.1 Growing number of clinical trials in Canada to drive market growth 109
FIGURE 34 CANADA: NUMBER OF CLINICAL TRIALS (2013–2017) 109
TABLE 47 CANADA: MACROECONOMIC INDICATORS 110
TABLE 48 CANADA: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 110
TABLE 49 CANADA: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 110
TABLE 50 CANADA: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 111
TABLE 51 CANADA: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 111

10.3 EUROPE 111
TABLE 52 EUROPE: RWE SOLUTIONS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 112
TABLE 53 EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 112
TABLE 54 EUROPE: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 55 EUROPE: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 113
TABLE 56 EUROPE: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 113
10.3.1 GERMANY 114
10.3.1.1 High pharmaceutical R&D spending in Germany to
boost the market growth 114
TABLE 57 GERMANY: MACROECONOMIC INDICATORS 114
TABLE 58 GERMANY: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 115
TABLE 59 GERMANY: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 115
TABLE 60 GERMANY: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 115
TABLE 61 GERMANY: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 116
10.3.2 UK 116
10.3.2.1 The growing adoption of HTA in the UK and favorable government initiatives are the key factors supporting market growth 116
TABLE 62 UK: MACROECONOMIC INDICATORS 117
TABLE 63 UK: RWE SOLUTIONS MARKET, BY COMPONENT, 2019–2026 (USD MILLION) 117
TABLE 64 UK: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 65 UK: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 118
TABLE 66 UK: RWE SOLUTIONS MARKET, BY END USER, 2019–2026 (USD MILLION) 118
10.3.3 FRANCE 118
10.3.3.1 High number of oncology clinical trials in France to
drive market growth 118
TABLE 67 FRANCE: MACROECONOMIC INDICATORS 119
TABLE 68 FRANCE: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 119
TABLE 69 FRANCE: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 120
TABLE 70 FRANCE: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 120
TABLE 71 FRANCE: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 120
10.3.4 ITALY 121
10.3.4.1 The demand for RWE in Italy is high due to the widespread use of pay-for-outcomes and coverage with evidence development 121
TABLE 72 ITALY: NUMBER OF CLINICAL TRIALS STARTED, BY COMPANY, 2017 121
TABLE 73 ITALY: MACROECONOMIC INDICATORS 122
TABLE 74 ITALY: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 122
TABLE 75 ITALY: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 122
TABLE 76 ITALY: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 123
TABLE 77 ITALY: RWE SOLUTIONS MARKET, BY END USER, 2019–2026 (USD MILLION) 123
10.3.5 SPAIN 123
10.3.5.1 Rising R&D expenditure to propel market growth in Spain 123
TABLE 78 SPAIN: MACROECONOMIC INDICATORS 124
TABLE 79 SPAIN: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 124
TABLE 80 SPAIN: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 124
TABLE 81 SPAIN: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 125
TABLE 82 SPAIN: RWE SOLUTIONS MARKET, BY END USER, 2019–2026 (USD MILLION) 125
10.3.6 REST OF EUROPE 125
TABLE 83 ROE: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 126
TABLE 84 ROE: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 85 ROE: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 126
TABLE 86 ROE: RWE SOLUTIONS MARKET, BY END USER, 2019–2026 (USD MILLION) 127
10.4 ASIA PACIFIC 127
FIGURE 35 ASIA PACIFIC: RWE SOLUTIONS MARKET SNAPSHOT 128
TABLE 87 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
TABLE 88 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 129
TABLE 89 ASIA PACIFIC: RWE DATA SETS MARKET, BY TYPE,
2019–2026 (USD MILLION) 129
TABLE 90 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 129
TABLE 91 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 130
10.4.1 JAPAN 130
10.4.1.1 Stringent regulatory scenario in Japan to restrain the market growth 130
TABLE 92 JAPAN: MACROECONOMIC INDICATORS 131
TABLE 93 JAPAN: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 131
TABLE 94 JAPAN: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 131
TABLE 95 JAPAN: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 132
TABLE 96 JAPAN: RWE SOLUTIONS MARKET, BY END USER, 2019–2026 (USD MILLION) 132
10.4.2 CHINA 133
10.4.2.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market growth 133
FIGURE 36 CHINA: ADULT WEARABLE DEVICE USER BASE AND
INTERNET PENETRATION (2015–2019) 133
FIGURE 37 CHINA: NUMBER OF OBSERVATIONAL STUDIES, 2013–2017 134
TABLE 97 CHINA: MACROECONOMIC INDICATORS 134
TABLE 98 CHINA: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 135
TABLE 99 CHINA: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 100 CHINA: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 135
TABLE 101 CHINA: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 136
10.4.3 REST OF ASIA PACIFIC 136
TABLE 102 ROAPAC: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 137
TABLE 103 ROAPAC: RWE DATA SETS MARKET, BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 104 ROAPAC: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 137
TABLE 105 ROAPAC: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 138
10.5 LATIN AMERICA 138
10.5.1 RISING INVESTMENTS AND HEALTHCARE EXPENDITURE SHOW POTENTIAL FOR MARKET GROWTH 138
TABLE 106 LATIN AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT,
2019–2026 (USD MILLION) 138
TABLE 107 LATIN AMERICA: RWE DATA SETS MARKET, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 108 LATIN AMERICA: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 139
TABLE 109 LATIN AMERICA: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 139
10.6 MIDDLE EAST & AFRICA 140
10.6.1 GROWING AVAILABILITY OF FUNDING IN THE MIDDLE EAST INDICATES OPPORTUNITIES FOR MARKET GROWTH 140
TABLE 110 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2019–2026 (USD MILLION) 140
TABLE 111 MIDDLES EAST & AFRICA: RWE DATA SETS MARKET, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 112 MIDDLE EAST & AFRICA: RWE SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 141
TABLE 113 MIDDLE EAST & AFRICA: RWE SOLUTIONS MARKET, BY END USER,
2019–2026 (USD MILLION) 141
11 COMPETITIVE LANDSCAPE 142
11.1 INTRODUCTION 142
FIGURE 38 KEY DEVELOPMENTS BY MAJOR PLAYERS BETWEEN
JANUARY 2017 AND JULY 2021 142
11.2 COMPETITIVE BENCHMARKING 143
11.2.1 END-USER FOOTPRINT OF COMPANIES 143
11.2.2 PRODUCT FOOTPRINT OF COMPANIES 144
11.2.3 REGIONAL FOOTPRINT OF COMPANIES 145
11.3 REAL-WORLD EVIDENCE SOLUTIONS MARKET: R&D EXPENDITURE 146
FIGURE 39 R&D EXPENDITURE OF KEY PLAYERS IN THE REAL-WORLD EVIDENCE SOLUTIONS MARKET (2019 VS. 2020) 146
11.4 REVENUE ANALYSIS OF KEY MARKET PLAYERS 146
FIGURE 40 REAL-WORLD EVIDENCE SOLUTIONS MARKET: REVENUE ANALYSIS
OF KEY MARKET PLAYERS (2020) 146
11.5 COMPETITIVE LEADERSHIP MAPPING 147
11.5.1 STARS 147
11.5.2 EMERGING LEADERS 147
11.5.3 PERVASIVE PLAYERS 147
11.5.4 EMERGING COMPANIES 147
FIGURE 41 COMPETITIVE LEADERSHIP MAPPING: REAL-WORLD EVIDENCE SOLUTIONS MARKET, 2020 148
11.6 COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES 148
11.6.1 PROGRESSIVE COMPANIES 148
11.6.2 STARTING BLOCKS 149
11.6.3 RESPONSIVE COMPANIES 149
11.6.4 DYNAMIC COMPANIES 149
FIGURE 42 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES 150
11.7 MARKET RANKING ANALYSIS 150
FIGURE 43 REAL-WORLD EVIDENCE SOLUTIONS MARKET RANKING ANALYSIS,
BY KEY PLAYER, 2020 151
11.8 COMPETITIVE SITUATION AND TRENDS 152
11.8.1 SOLUTION LAUNCHES 152
11.8.2 DEALS 152
11.8.3 OTHER DEVELOPMENTS 153
12 COMPANY PROFILES 154
12.1 KEY PLAYERS 154
(Business Overview, Solutions/ Services Offered, Recent Developments, and MnM View)*
12.1.1 IQVIA 154
TABLE 114 IQVIA: BUSINESS OVERVIEW 154
FIGURE 44 IQVIA: COMPANY SNAPSHOT (2020) 155
12.1.2 IBM 158
TABLE 115 IBM CORPORATION: BUSINESS OVERVIEW 158
FIGURE 45 IBM CORPORATION: COMPANY SNAPSHOT (2020) 159
12.1.3 OPTUM (A SUBSIDIARY OF THE UNITED HEALTH GROUP, INC.) 162
TABLE 116 OPTUM, INC: BUSINESS OVERVIEW 162
FIGURE 46 OPTUM: COMPANY SNAPSHOT (2020) 162
12.1.4 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC 166
TABLE 117 PPD: BUSINESS OVERVIEW 166
FIGURE 47 PPD: COMPANY SNAPSHOT (2020) 167
12.1.5 PAREXEL INTERNATIONAL CORPORATION 170
TABLE 118 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW 170
12.1.6 PERKINELMER 172
TABLE 119 PERKINELMER: BUSINESS OVERVIEW 172
FIGURE 48 PERKINELMER: COMPANY SNAPSHOT (2020) 173
12.1.7 ICON PLC 174
TABLE 120 ICON PLC: BUSINESS OVERVIEW 174
FIGURE 49 ICON PLC: COMPANY SNAPSHOT (2020) 174
12.1.8 ORACLE 176
TABLE 121 ORACLE: BUSINESS OVERVIEW 176
FIGURE 50 ORACLE: COMPANY SNAPSHOT (2020) 177
12.1.9 COGNIZANT 179
TABLE 122 COGNIZANT: BUSINESS OVERVIEW 179
FIGURE 51 COGNIZANT: COMPANY SNAPSHOT (2020) 179
12.1.10 SYNEOS HEALTH 181
TABLE 123 SYNEOS HEALTH: BUSINESS OVERVIEW 181
FIGURE 52 SYNEOS HEALTH: COMPANY SNAPSHOT (2020) 182
12.1.11 ANTHEM 184
TABLE 124 ANTHEM, INC.: BUSINESS OVERVIEW 184
FIGURE 53 ANTHEM, INC.: COMPANY SNAPSHOT (2020) 184
12.1.12 CLINIGEN 186
TABLE 125 CLINIGEN: BUSINESS OVERVIEW 186
FIGURE 54 CLINIGEN: COMPANY SNAPSHOT (2020) 187
12.1.13 SAS INSTITUTE 188
TABLE 126 SAS INSTITUTE: BUSINESS OVERVIEW 188
FIGURE 55 SAS INSTITUTE: COMPANY SNAPSHOT (2020) 189
12.1.14 CERNER CORPORATION 191
TABLE 127 CERNER CORPORATION: BUSINESS OVERVIEW 191
FIGURE 56 CERNER CORPORATION: COMPANY SNAPSHOT (2020) 192
12.1.15 CEGEDIM HEALTH DATA 194
TABLE 128 CEGEDIM HEALTH DATA: BUSINESS OVERVIEW 194
12.1.16 AETION 196
TABLE 129 AETION: BUSINESS OVERVIEW 196
12.1.17 TRINETX 198
TABLE 130 TRINETX: BUSINESS OVERVIEW 198
12.1.18 TRINITY 201
TABLE 131 TRINITY: BUSINESS OVERVIEW 201
12.1.19 VERANTOS 202
TABLE 132 VERANTOS: BUSINESS OVERVIEW 202

12.1.20 MEDPACE HOLDINGS 203
TABLE 133 MEDPACE HOLDINGS: BUSINESS OVERVIEW 203
FIGURE 57 MEDPACE HOLDINGS: COMPANY SNAPSHOT (2020) 203
* Business Overview, Solutions/ Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 205
12.2.1 SYAPSE 205
12.2.2 CIOX HEALTH 205
12.2.3 TEMPUS 206
12.2.4 FLATIRON HEALTH 206
12.2.5 SCIFORMIX 207
13 APPENDIX 208
13.1 DISCUSSION GUIDE 208
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 212
13.3 AVAILABLE CUSTOMIZATIONS 214
13.4 RELATED REPORTS 214
13.5 AUTHOR DETAILS 215